scholarly journals Nestin: Neural Stem/Progenitor Cell Marker in Brain Tumors

10.5772/52634 ◽  
2013 ◽  
Author(s):  
Yoko Matsuda ◽  
Hisashi Yoshimura ◽  
Taeko Suzuki ◽  
Toshiyuki Ishiwat
Keyword(s):  
Brain Tumors ◽  
Progenitor Cell ◽  
Cell Marker

TAMI-36. TAMEP ARE BRAIN TUMOR PARENCHYMAL CELLS CONTROLLING NEOPLASTIC ANGIOGENESIS AND PROGRESSION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi205-vi206
Author(s):  
Roland Kälin ◽  
Linzhi Cai ◽  
Yuping Li ◽  
Ines Hellmann ◽  
Rainer Glass
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Single Cell ◽  
Disease Progression ◽  
Progenitor Cell ◽  
Local Environment ◽  
Lineage Tracing ◽  
Immunofluorescence Analysis ◽  
Progenitor Cell Population ◽  
Parenchymal Cells

Abstract Aggressive brain tumors like glioblastoma depend on support by their local environment and subsets of tumor-parenchymal cells may promote specific phases of disease-progression. We investigated the glioblastoma microenvironment with transgenic lineage-tracing models, intravital imaging, single-cell transcriptomics, immunofluorescence analysis as well as histopathology and characterized a previously unacknowledged population of tumor-associated cells with a myeloid-like expression profile (TAMEP) that transiently appeared during glioblastoma growth. TAMEP of mice and humans were identified with specific markers. Strikingly, TAMEP did not derive from microglia or peripheral monocytes but were generated by a fraction of CNS-resident, SOX2-positive progenitors. Abrogation of this progenitor cell-population, by conditional Sox2-knockout, drastically reduced glioblastoma-vascularization and -size. TAMEP manipulation profoundly altered vessel function and strongly attenuated the blood-tumor barrier. Hence, our data indicate TAMEP and their progenitors as new targets for glioblastoma therapy.

Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors

2010 ◽  
pp. n/a-n/a
Author(s):  
Mahshid Malakootian ◽  
Seyed Javad Mowla ◽  
Hooshang Saberi ◽  
Malek Hossein Asadi ◽  
Yaser Atlasi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumors ◽  
Differential Expression ◽  
Stem Cell Marker ◽  
Cell Marker ◽  
Different Types

Increased Activity of Aldehyde Dehydrogenase, a Stem/Progenitor Cell Marker, in Chronic Lymphocytic Leukemia,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3867-3867
Author(s):  
Raymond P. Wu ◽  
Christina C.N. Wu ◽  
Tomoko Hayashi ◽  
Laura Z. Rassenti ◽  
Thomas J. Kipps ◽  
...  
Keyword(s):  
B Cells ◽  
Chronic Lymphocytic Leukemia ◽  
Board Of Directors ◽  
Research Funding ◽  
Progenitor Cell ◽  
Lymphocytic Leukemia ◽  
Cell Marker ◽  
Aldh Activity ◽  
Advisory Committees ◽  
Aldefluor Assay

Abstract Abstract 3867 Introduction: Despite their mature appearance, the B cells from chronic lymphocytic leukemia (CLL) possess immature characteristics both functionally and biochemically. CLL B cells display known biochemical markers characteristic of cells early in the blood lineage, including ROR1, Wnt16, and LEF1. In addition, CLL B cells have higher levels of Reactive Oxygen Species (ROS) and of the oxidant-induced transcription factor Nrf2 [NFE2L2], compared to normal peripheral blood mononuclear cells (PBMC). Intracellular ROS status has been suggested to be a marker of cancer stem/progenitor cells possibly due to their high expression of oncogenes. Downstream targets of Nrf2 include the Aldehyde dehydrogenase [ALDH] enzymes, which are believed to play a crucial role in stem cell biology because they protect the cells against oxidative stress caused by accumulation of aldehydes. Here, we use ALDH activity to visualize populations of CLL B cells that may have stem/progenitor properties. Materials and Methods: Isolated PBMC from normal donors and CLL patients with aggressive and indolent disease were stained for ALDH activity with an Aldefluor assay kit (StemCell Technologies). The ALDH inhibitor, diethylaminobenzaldehyde (DEAB), was used to confirm that the fluorescent activity was due to ALDH activity. At the end of the Aldefluor assay, the cells were stained for cell surface markers, CD19, CD5, CD38 and CD34. 50,000 total events were collected for FACS analysis. Normalized Mean Fluorescence Intensity (MFI) values were calculated by dividing each MFI value to average MFI value of normal CD19+ cells for each experiment. Data analyses were performed by FlowJo software and Prizm. P-values were calculated by One-Way ANOVA analysis with Post-Bonferroni's multiple comparison test. Results: We examine the level of ALDH expression and activity in CD19+ cells of healthy donors (n = 9), CLL samples that expressed unmutated IgVH and that were ZAP-70 positive (defined as “aggressive”, n = 14) or samples that expressed mutated IgVH and were ZAP-70 negative (defined as “indolent”, n=12). CLL B cells from patients with aggressive disease had significantly higher ALDH activities compared to normal B cells (p < 0.001) and indolent CLL B cells (p < 0.05) (Figure1). Indolent CLL B cells also have higher level of ALDH activities compared to normal B cells (p < 0.01) (Figure1). Treatment with the ALDH inhibitor, DEAB, suppressed the increased fluorescence observed in CLL B cells. In addition, ALDH high CLL B cells are CD34 negative. These data show that CLL B cells express a marker known to be associated with stem/progenitor cells, but these populations are different from CD34 positive hematopoietic stem cells. In addition, our data show that a stem/progenitor cell marker is associated with the pathogenesis of CLL. Disclosures: Kipps: Igenica: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Abbot Industries: Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; GSK: Research Funding; Gilead Sciences: Consultancy, Research Funding; Amgen: Research Funding.

Clinicopathological significance of expression of nestin, a neural stem/progenitor cell marker, in human glioma tissue

2013 ◽  
Vol 31 (3) ◽  
pp. 162-171 ◽  
Author(s):  
Takehiro Tomita ◽  
Jiro Akimoto ◽  
Jo Haraoka ◽  
Motoshige Kudo
Keyword(s):  
Progenitor Cell ◽  
Cell Marker ◽  
Human Glioma ◽  
Glioma Tissue ◽  
Clinicopathological Significance

scholarly journals The Neural Stem/Progenitor Cell Marker Nestin Is Expressed in Proliferative Endothelial Cells, but Not in Mature Vasculature

2010 ◽  
Vol 58 (8) ◽  
pp. 721-730 ◽  
Author(s):  
Sayuri Suzuki ◽  
Jun Namiki ◽  
Shinsuke Shibata ◽  
Yumi Mastuzaki ◽  
Hideyuki Okano
Keyword(s):  
Endothelial Cells ◽  
Progenitor Cell ◽  
Cell Marker

scholarly journals Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver

Hepatology ◽  
1998 ◽  
Vol 28 (4) ◽  
pp. 980-985 ◽  
Author(s):  
Heather A. Crosby ◽  
Stefan G. Hubscher ◽  
Ruth E. Joplin ◽  
Deirdre A. Kelly ◽  
Alastair J. Strain
Keyword(s):  
Progenitor Cell ◽  
Cell Marker ◽  
Pediatric Liver

scholarly journals Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas

2010 ◽  
Vol 299 (2) ◽  
pp. G303-G310 ◽  
Author(s):  
Randal May ◽  
Sripathi M. Sureban ◽  
Stan A. Lightfoot ◽  
Aimee B. Hoskins ◽  
Daniel J. Brackett ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stem Cell ◽  
Suspension Culture ◽  
Progenitor Cell ◽  
Expression Patterns ◽  
Stem Cell Marker ◽  
Nodule Formation ◽  
Cell Marker ◽  
Pancreatic Development ◽  
Cytokeratin 14

Stem cells are critical in maintaining adult homeostasis and have been proposed to be the origin of many solid tumors, including pancreatic cancer. Here we demonstrate the expression patterns of the putative intestinal stem cell marker DCAMKL-1 in the pancreas of uninjured C57BL/6 mice compared with other pancreatic stem/progenitor cell markers. We then determined the viability of isolated pancreatic stem/progenitor cells in isotransplantation assays following DCAMKL-1 antibody-based cell sorting. Sorted cells were grown in suspension culture and injected into the flanks of athymic nude mice. Here we report that DCAMKL-1 is expressed in the main pancreatic duct epithelia and islets, but not within acinar cells. Coexpression was observed with somatostatin, NGN3, and nestin, but not glucagon or insulin. Isolated DCAMKL-1+ cells formed spheroids in suspension culture and induced nodule formation in isotransplantation assays. Analysis of nodules demonstrated markers of early pancreatic development (PDX-1), glandular epithelium (cytokeratin-14 and Ep-CAM), and isletlike structures (somatostatin and secretin). These data taken together suggest that DCAMKL-1 is a novel putative stem/progenitor marker, can be used to isolate normal pancreatic stem/progenitors, and potentially regenerates pancreatic tissues. This may represent a novel tool for regenerative medicine and a target for anti-stem cell-based therapeutics in pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document